TITLE

Screening of Crude Plant Extracts with Anti-Obesity Activity

AUTHOR(S)
Changhyun Roh; Uhee Jung
PUB. DATE
February 2012
SOURCE
International Journal of Molecular Sciences;Feb2012, Vol. 13 Issue 2, p1710
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Obesity is a global health problem. It is also known to be a risk factor for the development of metabolic disorders, type 2 diabetes, systemic hypertension, cardiovascular disease, dyslipidemia, and atherosclerosis. In this study, we screened crude extracts from 400 plants to test their anti-obesity activity using porcine pancreatic lipase assay (PPL; triacylglycerol lipase, EC 3.1.1.3) in vitro activity. Among the 400 plants species examined, 44 extracts from plants, showed high anti-lipase activity using 2,4-dinitrophenylbutyrate as a substrate in porcine pancreatic lipase assay. Furthermore, 44 plant extracts were investigated for their inhibition of lipid accumulation in 3T3-L1 cells. Among these 44 extracts examined, crude extracts from 4 natural plant species were active. Salicis Radicis Cortex had the highest fat inhibitory activity, whereas Rubi Fructus, Corni Fructus, and Geranium nepalense exhibited fat inhibitory capacity higher than 30% at 100 µg/mL in 3T3-L1 adipocytes, suggesting anti-obesity activity. These results suggest that four potent plant extracts might be of therapeutic interest with respect to the treatment of obesity.
ACCESSION #
72673800

 

Related Articles

  • Reducing cardiovascular risk in patients with type 2 diabetes: management of dyslipidemia. Campbell, Jennifer; Hilleman, Daniel // Formulary;Apr2010, Vol. 45 Issue 4, p124 

    Cardiovascular disease (CVD) remains the leading cause of death in patients with diabetes mellitus, accounting for 50% of all deaths. Dyslipidemia is an important modifiable risk factor in diabetic patients and represents a key area for intervention in these patients. Diabetic patients have a...

  • Effects of rs7903146 Variation in the Tcf7l2 Gene in the Lipid Metabolism of Three Different Populations. Perez-Martinez, Pablo; Perez-Caballero, Ana I.; Garcia-Rios, Antonio; Yubero-Serrano, Elena M.; Camargo, Antonio; Gomez-Luna, Maria J.; Marin, Carmen; Gomez-Luna, Purificacion; Dembinska-Kiec, Aldona; Rodriguez-Cantalejo, Fernando; Tinahones, Francisco J.; Roche, Helen M.; Perez-Jimenez, Francisco; Lopez-Miranda, Jose; Delgado-Lista, Javier; Clarke, Robert // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Background: TCF7L2 rs7903146 is an important genetic factor predicting type 2 diabetes (T2DM) which has also been linked to higher cardiovascular risk. To date, there is little information about the additional impact of this single nucleotide polymorphism (SNP) beyond glucose metabolism....

  • The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes. Hollander, Priscilla // U.S. Endocrinology;Winter2013, Vol. 9 Issue 2, p101 

    The prevalence of diabetes continues to rise, following the rising rates of obesity. Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing long-term complications associated with the disease. Weight gain is also an...

  • The Effect of Hydro Alcoholic Nettle (Urtica dioica) Extracts on Insulin Sensitivity and Some Inflammatory Indicators in Patients with Type 2 Diabetes: A Randomized Double-blind Control Trial. Namazi, N.; Esfanjani, A. T.; Heshmati, J.; Bahrami, A. // Pakistan Journal of Biological Sciences;8/1/2011, Vol. 14 Issue 15, p775 

    Type 2 diabetes is a metabolic disorder that is strongly associated with cardiovascular risk. Inflammation is a potential risk factor for cardiovascular disease. In this study, hydro alcoholic extract of Nettle (Urtica dioica) on insulin sensitivity and some inflammatory indicators in type 2...

  • Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. van Heek, Margaret; Austin, Theodore M.; Farley, Constance; Cook, John A.; Tetzloff, Glen G.; Davis, Harry R.; van Heek, M; Austin, T M; Farley, C; Cook, J A; Tetzloff, G G; Davis, H R // Diabetes;Jun2001, Vol. 50 Issue 6, p1330 

    Ezetimibe potently and selectively inhibits cholesterol absorption in the intestine, thereby reducing plasma cholesterol in preclinical models of hypercholesterolemia. Clinical trials have demonstrated that ezetimibe lowers LDL cholesterol and raises HDL cholesterol in humans. The effect of...

  • Current models and strategies in the development of antiobesity drugs. Kinsey‐Jones, James S.; Murphy, Kevin G. // Annals of the New York Academy of Sciences;Dec2011, Vol. 1245 Issue 1, p3 

    Animal models have enabled investigation of the complex mechanisms underlying energy homeostasis and, therefore, the development of antiobesity drugs.

  • Diabetic ketoacidosis associated with atypical antipsychotic drug, clozapine treatment: Report of a case and review of literature. Pillai, L.; Husainy, S. M. K.; Ramchandani, K. // Indian Journal of Critical Care Medicine;Jul-Sep2006, Vol. 10 Issue 3, p193 

    Atypical antipsychotic drugs are associated with metabolic disturbances like weight gain, type 2 diabetes hyperglycaemia and dyslipedemia, which can result in serious health risk in patients. Diabetic ketoacidosis resulting in serious metabolic acidosis, occurring in a schizophrenic patient on...

  • Programming other hormones that affect insulin. Byrne, Christopher D. // British Medical Bulletin;Nov2001, Vol. 60 Issue 1, p153 

    The metabolic syndrome is associated with a marked increase in risk of type 2 diabetes and atherosclerotic vascular disease (AVD). The mechanism responsible for the metabolic syndrome is uncertain, but recent evidence suggests that a combination of low birth weight and adult obesity is...

  • Advancing drug therapy of the metabolic syndrome. Grundy, Scott M // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p341 

    The metabolic syndrome — a group of factors that raise the risk of cardiovascular disease and type 2 diabetes — is increasingly common. How might the challenges of developing improved therapies to normalize these risk factors be approached?

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics